Advertisement
U.S. Markets closed

Innate Pharma S.A. (IPHA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Visitors trend2W10W9M
1.5000+0.0200 (+1.35%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.4800
Open1.4800
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4800 - 1.5002
52 Week Range1.2900 - 3.1500
Volume9,682
Avg. Volume10,279
Market Cap134.302M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-0.4400
Earnings DateNov 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.41
  • Business Wire

    Innate Pharma Releases Its 2025 Financial Calendar

    MARSEILLE, France, November 20, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2025 financial calendar:

  • Business Wire

    Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

    MARSEILLE, France, November 19, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate’s proprietary NK cell engager including an IL-2v and targeting CD20 from the ANKET® platform. IPH6501 is currently evaluated in a Phase 1/2 clinical trial in B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654).